SPT-320 · program

GlyphAgo (SPT-320) for Generalized anxiety disorder

Phase 2RecruitingSeaport Therapeutics (SPTX)

GlyphAgo (SPT-320), an oral lymphatic-absorption prodrug of agomelatine, for generalized anxiety disorder (GAD), Seaport Therapeutics' second clinical program. A multipart Phase 1 trial in about 174 healthy volunteers in Australia (SAD, food-effect/oral-contraceptive crossover and seven-day MAD; protocol SPT-320-2024-101) began in September 2025 and completed in 2026: GlyphAgo raised agomelatine bioavailability 6.8-fold over unmodified agomelatine (above the program's 2-fold target), cut PK variability 10-fold, showed no food or oral-contraceptive effect, and produced no serious, severe or liver-related adverse events and no clinically significant changes in ALT, AST or bilirubin. On 2026-10-07 Seaport dosed the first patient in a six-week, randomized, double-blind Phase 2a proof-of-pharmacology trial in Australia in adults with GAD and sleep disturbance (16 or 32 mg/day; sleep endpoints by Insomnia Severity Index and EEG sleep architecture, plus HAM-A and CGI-S), with topline expected in early 2028. A global, randomized, placebo-controlled Phase 2/3 trial in GAD (earlier described as a potentially registration-enabling Phase 2b) is planned to start in 1H 2027 with topline by year-end 2028. No regulatory designations disclosed.

Development timeline

Phase 2Oct 2026 – Dec 2028
  1. UpcomingTopline from the planned global, randomized, placebo-controlled Phase 2/3 trial of GlyphAgo in GAD (start planned 1H 2027), expected by year-end 2028.↗
  2. UpcomingTopline from the Phase 2a proof-of-pharmacology trial of GlyphAgo in GAD with sleep disturbance (sleep by ISI and EEG; HAM-A, CGI-S), expected early 2028.↗
  3. Conference presentationGlyphAgo Phase 1 pharmacokinetic data presented at ECNP 2026↗
  4. First patient dosed in the six-week, randomized, double-blind Phase 2a trial in adults with GAD and sleep disturbance in Australia (16 or 32 mg/day). Announcement date used.↗
  5. Trial startedFirst patient dosed in Phase 2a trial of GlyphAgo in GAD with sleep disturbance↗
Phase 1Sept 2025 – Jun 2026
  1. metPhase 1 MAD topline: seven-day dosing of GlyphAgo reached therapeutic agomelatine exposures at doses projected to avoid liver enzyme elevations; dose-dependent AUC and Cmax; no serious or liver-related adverse events.↗
  2. Phase 1 ResultsPositive Phase 1 multiple-ascending dose results for GlyphAgo↗
  3. metPhase 1 SAD and crossover topline: GlyphAgo gave a 6.8-fold increase in agomelatine bioavailability (90% CI 4.7-10.0) and 10-fold lower PK variability vs unmodified agomelatine, exceeding the 2-fold target; 9.6-14.5-fold higher dose-normalized exposure in SAD; no liver-related adverse events.↗
  4. Phase 1 ResultsPositive Phase 1 SAD and crossover results for GlyphAgo↗
  5. Seaport announced dosing of the first participant in the multipart Phase 1 trial of GlyphAgo in healthy adult volunteers (SAD, MAD and food-effect crossover; open-label and placebo-controlled). Announcement date used; the true first dose is on or before it.↗
  6. Trial startedFirst participant dosed in Phase 1 trial of GlyphAgo (SPT-320)↗

Readouts

  • By year-end 2028AnticipatedTopline data

    Topline from the planned global, randomized, placebo-controlled Phase 2/3 trial of GlyphAgo in GAD (start planned 1H 2027), expected by year-end 2028. ↗

  • Early 2028AnticipatedTopline data

    Topline from the Phase 2a proof-of-pharmacology trial of GlyphAgo in GAD with sleep disturbance (sleep by ISI and EEG; HAM-A, CGI-S), expected early 2028. ↗

  • 2026-06-08ReportedTopline datamet

    Phase 1 MAD topline: seven-day dosing of GlyphAgo reached therapeutic agomelatine exposures at doses projected to avoid liver enzyme elevations; dose-dependent AUC and Cmax; no serious or liver-related adverse events. ↗

  • 2026-04-02ReportedTopline datamet

    Phase 1 SAD and crossover topline: GlyphAgo gave a 6.8-fold increase in agomelatine bioavailability (90% CI 4.7-10.0) and 10-fold lower PK variability vs unmodified agomelatine, exceeding the 2-fold target; 9.6-14.5-fold higher dose-normalized exposure in SAD; no liver-related adverse events. ↗

Clinical trials in Generalized anxiety disorder

Phase 2Recruiting

Phase 2a randomized, double-blind proof-of-pharmacology trial of GlyphAgo (SPT-320) in adults with generalized anxiety disorder and sleep disturbance - Australia

Started Oct 2026

SPT-320-2024-101Phase 1Completedn=174

Multipart Phase 1 proof-of-concept trial of GlyphAgo (SPT-320) in healthy volunteers (SAD, food-effect/oral-contraceptive crossover vs agomelatine, MAD) - Australia

Started Sept 2025

Formulations

FormulationRouteRegimenPharmacokinetics
GlyphAgo (SPT-320) oral, once dailyGlyph lymphatic-absorption prodrug
Phase 2a: 16 mg/day (about 5 mg agomelatine) or 32 mg/day (about 10 mg agomelatine) for six weeks. Phase 1: single ascending doses containing 2.5, 5 and 10 mg agomelatine equivalents, a food-effect/oral-contraceptive crossover against agomelatine 25 mg, and seven-day once-daily multiple ascending doses including 16 mg and 32 mg.
OralOnce daily—

Mechanism of action (compound-wide)

SPT-320 is a prodrug; its pharmacology is that of the released parent, agomelatine, a melatonin MT1/MT2 receptor agonist and serotonin 5-HT2C receptor antagonist that is an approved anxiolytic and antidepressant outside the US. The Glyph modification moves absorption to the gut lymphatics (in preclinical work over 50% of agomelatine was transported through the mesenteric lymphatics) to avoid first-pass liver metabolism and lower liver exposure.

TargetActionAffinity
MT1primaryMTNR1AAgonist—ⓘ
5-HT2CHTR2CAntagonist—ⓘ
MT2MTNR1BAgonist—ⓘ

← Full SPT-320 compound page (identity, identifiers, all indications)

Sources

  1. Bonner D, et al. GlyphAgo demonstrated 6.8-fold bioavailability and 10-fold reduced variability versus unmodified agomelatine (ECNP 2026, PS02-2029) — CNS Pulse (ECNP 2026 abstract)
  2. First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance (2026-10-07) — Psychiatric Times
  3. GlyphAgo for Treatment of Anxiety Shows Positive Phase 1 Topline Results (2026-04-02) — Psychiatric Times
  4. Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo (SPT-320) in Healthy Volunteers (2025-09-11) — Seaport Therapeutics
  5. Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (2026-06-08, Business Wire copy) — Seaport Therapeutics (via BioSpace)